Vaxcyte (PCVX) Cash from Operations (2019 - 2026)
Vaxcyte (PCVX) posted quarterly Cash from Operations of 280625000.0 for Q1 2026, down 68.77% year-over-year from 898650718.37 in Q1 2025, and down 24.82% quarter-over-quarter from 224832000.0 in Q4 2025.
Vaxcyte (PCVX) Cash from Operations (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported Cash from Operations for 8 consecutive years, with 280625000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 68.77% year-over-year to 280625000.0; the TTM figure through Mar 2026 stood at 769928000.0 (down 67.46% YoY), while the FY2025 annual figure was 655577000.0, down 44.84% from the prior year.
- Cash from Operations fell to 280625000.0 in Q1 2026 per PCVX's latest filing, from 224832000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 27702000.0 in Q1 2022 and bottomed at 280625000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 109189176.47 across 5 years, with a median of 111401000.0 in 2024.
- On a YoY basis, Cash from Operations climbed as much as 13.52% in 2024 and fell as far as 233.66% in 2024.
- Vaxcyte's Cash from Operations stood at 65221000.0 in 2022, then sank by 97.5% to 128810000.0 in 2023, then increased by 13.52% to 111401000.0 in 2024, then tumbled by 101.82% to 224832000.0 in 2025, then fell by 24.82% to 280625000.0 in 2026.
- Business Quant data shows PCVX's Cash from Operations at 280625000.0 in Q1 2026, 224832000.0 in Q4 2025, and 143305000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - | -232.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -232.47 Mn |
| Jun 30, 2026 | -232.47 Mn |
| Mar 31, 2026 | -280.63 Mn |
| Mar 31, 2026 | -280.63 Mn |
| Dec 31, 2025 | -224.83 Mn |
| Dec 31, 2025 | -224.83 Mn |
| Sep 30, 2025 | -143.31 Mn |
| Sep 30, 2025 | -143.31 Mn |
| Jun 30, 2025 | -121.17 Mn |
| Jun 30, 2025 | -121.17 Mn |
| Mar 31, 2025 | -166.27 Mn |
| Mar 31, 2025 | -166.27 Mn |
| Dec 31, 2024 | -111.40 Mn |
| Dec 31, 2024 | -111.40 Mn |
| Sep 30, 2024 | -60.71 Mn |
| Sep 30, 2024 | -60.71 Mn |
| Jun 30, 2024 | -121.39 Mn |
| Jun 30, 2024 | -121.39 Mn |
| Mar 31, 2024 | -159.12 Mn |
| Mar 31, 2024 | -159.12 Mn |